Answers are grounded in this paper and cite their sources.
INTRODUCTION: HER2-targeted antibody-drug conjugates (ADCs) have shown promising outcomes in the treatment of patients with various HER2-expressing solid tumors. The efficacy of ADCs is influenced by several factors, such as the antibody properties, linker design, payload type and potency, drug-to-antibody ratio, and target antigen expression. AREAS COVERED: This review specifically examines target antigen expression and the companion diagnostic (CDx) assays used to select patients for treatment with HER2-targeted ADCs. Pivotal clinical trials involving the two FDA-approved HER2-targeted ADCs, trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), were identified and assessed to determine whether they included data on efficacy outcomes associated with varying levels of HER2 expression. In addition, the clinical utility of the current FDA-approved HER2 CDx assays for selecting patients eligible for treatment with HER2-targeted ADCs is also discussed. EXPERT OPINION: High HER2 expression (IHC 3+) markedly affects the efficacy of T-DM1 and T-DXd in various solid tumors. Current data suggest that IHC should be used as the primary CDx assay to select patients for treatment with HER2-targeted ADCs. This recommendation aligns with the mechanism of action of ADCs, wherein increased receptor density facilitates receptor-mediated endocytosis of the drug molecules.
No takes yet. Share an insight, caveat, or question.
Jørgensen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: